




Tolerance and Autoimmunity

Lecture 19 April 20, 2009 Dr. Raveche

- Pathways : Deletion/Anergy
- Central v.s. Peripheral Tolerance
- Factors Involved in Induction of Tolerance
- Define mechanisms that lead to Autoimmunity



Tolerance



Autoimmunity

- Tolerance means the inability to make a positive immune response to a **specific antigen**

- Tolerance is **not global** unresponsiveness to all
- antigens (ie immunodeficient patient or patient receiving immunosuppressive drugs)
- Tolerance is usually achieved by **prior exposure** to specific antigens
- Normally we are **tolerant to self** antigens

Antigen	Effect of response to antigen	
	Normal response	Deficient response
Infectious agent	Protective immunity	Recurrent infection
Innocuous substance	Allergy	No response
Grafted organ	Rejection	Acceptance
Self organ	Autoimmunity	Self tolerance
Tumor	Tumor immunity	Cancer

Fig 1.32 © 2001 Garland Science

Central tolerance




Figure 16-1a
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W.H. Freeman and Company

Central Tolerance is Maintained by


Clonal Deletion--removal of antigen reactive cells

Main mechanism is **apoptosis: programmed cell death**

**Consequence of immature self-reactive lymphocytes
recognizing self-antigen**


Peripheral tolerance

Mature lymphocytes



**Immune response
to foreign antigens**

**Self
antigen**



**Peripheral tolerance:
deletion or anergy
of lymphocytes that
recognize self antigens
in peripheral tissues**




Figure 16-2
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W.H. Freeman and Company




Figure 16-3a
Kuby IMMUNOLOGY, Sixth Edition
 © 2007 W. H. Freeman and Company

Central

→ = Mean Fluorescence Intensity, green shaded area are cells with no reactivity to HEL




Figure 11-14b
Kuby IMMUNOLOGY, Sixth Edition
 © 2007 W. H. Freeman and Company

- Normal mice do not have detectable numbers of B cells reactive to hen egg lysozyme (naïve B cells have different BCRs with no exposure to Ag, no clonality)
- 2. Single transgenic >90% of anti-HEL transgenic mice have mIgM reactive with HEL (no Ag injection required these are naïve B cells)
- 3. Double transgenic: All B (except those that undergo receptor editing) react to HEL, however HEL Ag is also present in periphery--anergy occurs by downregulation of membrane IgM expression

Immature B cells Undergo Receptor Edit

Immature B cells that encounter Ag in bone marrow undergo apoptosis *UNLESS*

- **RAG genes are reactivated**
- **Additional light chain VJ recombination**
- **New light chain produced**
- **Different Ig receptor which does not react with Ag present in bone marrow**

<div>TABLE 11-3</div> <div>Expression of anti-HEL transgene by mature peripheral B cells in single- and double-transgenic mice</div>				
Experimental group	HEL level	Membrane anti-HEL	Anti-HEL PFC/spleen*	Anti-HEL serum titer*
Anti-HEL single transgenics	None	+	High	High
Anti-HEL/HEL double transgenics (group 1)	10^{-9} M	+	Low	Low
<p>*Experimental animals were immunized with hen egg-white lysozyme (HEL). Several days later, hemolytic plaque assays for the number of plasma cells secreting anti-HEL antibody were performed and the serum anti-HEL titers were determined. PFC = plaque-forming cells.</p> <p>SOURCE: Adapted from C. C. Goodnow, 1992, <i>Annual Review of Immunology</i> 10:489.</p>				

Table 11-3
 Kuby IMMUNOLOGY, Sixth Edition
 © 2007 W. H. Freeman and Company

T Cells Undergo Peripheral Tolerance of CD4+T due to:

Regulatory T cells: mediated by cytokines


Clonal Anergy

Activation Induced Cell Death:

Passive: no survival Stimuli

Active: FasL (privileged site)

**Transgenic mouse
expresses HEL
as self antigen**



**Syngeneic anti-HEL B cells
introduced to periphery**

*Thymic Selection
deletes HEL reactive
T cells (HEL now
self-antigen)*




Figure 16-3b
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W. H. Freeman and Company




Figure 16-4
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W. H. Freeman and Company

Regulatory T cells


CD4⁺, CD25⁺(bright)

**Treg: Develop in thymus
express CTLA-4
express FoxP3 (transcription factor)
PRODUCE: IL-10 AND TGF**


**Tr1 : Suppress Th1 (are antigen specific)
Usually IL-10 cytokine mediated (TGF- β too)
Ag in periphery**

Th3: Suppression Usually TGF beta cytokine mediated

Mechanisms of homeostasis in immune responses (T cells)



From Abbas, Lichtman, & Pober: Cellular and Molecular Immunology. W.B. Saunders, 1999, Fig. 10-14



B7 Costimulatory Pathways

- B7-2 on APC (constitutive), B7-1 appears later
- Receptors...
 - CD28 (low affinity-constitutive on T cells, surface expression)
 - CTLA-4 CD152 (high affinity cytoplasmic and upon stimulation becomes surface)

CD28 mediates:

- T cell proliferation
- Induction of bcl-xl
- Increase in CD40L (CD154)
- Differentiation of CD8+CTL
- Cytokine production

CTLA-4 (CD152)

- Induces apoptosis
- KO mice have LPD

T Cells Undergo Peripheral Tolerance of CD4+T due to:

Activation-Induced Cell Death

Apoptosis: Activation of cysteine proteases, caspases

Not Necrosis

Triggered by ligand binding to receptors (Fas, TNFR)

Characterized by DNA cleavage


Nuclear fragmentation

plasma membrane blebbing

phagocytosis of apoptotic bodies

Prevented by inhibitors of caspases (FLIP)

activation of Bcl family



Factors Involved in Tolerance

Tolerance is easier to achieve in newborns


Nature of antigen- soluble antigens are better tolerogens

Route of antigen administration--oral good for tolerance

Dose of antigen

Inefficient antigen presentation leads to T cell tolerance

Neonatal tolerance to allografts



From Abbas, Lichtman, & Pober: Cellular and Molecular Immunology. W.B. Saunders, 1999, Fig. 10-2

Immunologically privileged sites

Brain

Eye

Testis

Uterus (fetus)

Hamster cheek pouch

Autoimmunity


→ → **Describe Mechanisms responsible for autoimmune damage**

→ → **Name autoimmune diseases and major self-antigen**


Autoimmunity is a breakdown in tolerance
Immune hyperactivity, self recognition
Normally, tolerant to self antigens

Autoimmune Diseases can be Systemic or Organ-Specific


a Weakly stimulating self-antigen



b Stimulating self-antigen



c Foreign antigen



Overall Mechanism

- Autoimmune diseases results from breakdown of self-tolerance in B cells, or T cells, or both.
- Genetic, hormonal and environmental factors or infectious agents may contribute to the development of autoimmune diseases.
- Damage may be due to immune complexes, circulating autoantibodies, and/or autoreactive T
- Once initiated, autoimmune reactions may injure tissues and cause the release and alteration of other tissue antigens resulting in activation of lymphocytes specific for these other antigens.




Mechanism	Disruption of cell or tissue barrier	Infection of antigen-presenting cell	Binding of pathogen to self protein
Effect	Release of sequestered self antigen; activation of nontolerized cells	Release of inflammatory mediators, notably IFN- α	Pathogen acts as carrier to allow anti-self response
Example	Sympathetic ophthalmia	? SLE	? Interstitial nephritis ? SLE
			

Figure 13-26 part 1 of 2 Immunobiology, 6/e. (© Garland Science 2005)








Mechanism	Molecular mimicry	Superantigen
Effect	Production of cross-reactive antibodies or T cells	Polyclonal activation of autoreactive T cells
Example	<p>Rheumatic fever ? Diabetes ? Multiple sclerosis</p> 	<p>? Rheumatoid arthritis</p> 

Figure 13-26 part 2 of 2 Immunobiology, 6/e. (© Garland Science 2005)


Type II		Type III	Type IV
IgG antibody		IgG antibody	T _H 1
Cell- or matrix-associated antigen	Cell-surface receptors	Soluble antigen	Soluble antigen
Complement, FcR ⁺ cells (phagocytes, NK cells)	Antibody alters signaling	Complement Phagocytes	Macrophage activation
			
Some drug allergies (eg penicillin), transfusion reaction, autoimmune hemolytic anemia		Serum sickness, Systemic lupus erythematosus	Contact dermatitis, graft rejection, rheumatoid arthritis

ing

a Hashimoto's thyroiditis



b Graves' disease



STIMULATING AUTO-ANTIBODIES (Graves' disease)




Figure 16-8
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W. H. Freeman and Company




Figure 16-5a
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W. H. Freeman and Company

Normal thyroid follicle lined with




Figure 16-5b
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W. H. Freeman and Company


Thyroid follicle in Hashimoto's thyroiditis with
lymphocytic infiltration

Type III hypersensitivity

Mechanisms of
Ab deposition

Effector mechanisms
of tissue injury

B Immune complex – mediated tissue injury



Abbas 18-1B

Table 18–3. Examples of Human Immune Complex–Mediated Diseases

Disease	Antigen involved	Clinicopathologic manifestations
Systemic lupus erythematosus	DNA, nucleoproteins, others	Nephritis, arthritis, vasculitis
Polyarteritis nodosa	Hepatitis B virus surface antigen	Vasculitis
Poststreptococcal glomerulonephritis	Streptococcal cell wall antigen(s); may be "planted" in glomerular basement membrane	Nephritis
Serum sickness	Various proteins	Arthritis, vasculitis, nephritis





Possible Causes of Immune Complex Deposition

- Size of complex - small complexes are not always phagocytosed & can be deposited in vessels.
- Charge - cationic antigens bind to negatively charged components of the basement membranes of blood vessels and kidney glomeruli.
- Sites of high hydrostatic pressure (kidney).
- Following activation of inflammatory cells and mast cells - cytokines & vasoactive mediators are released leading to increased adhesion of leukocytes to endothelium, increased vascular permeability and enlarged interendothelial spaces allowing deposition of complexes.

Pathologic features of antibody-mediated glomerulonephritis

(A) Anti-basement membrane
antibody-mediated
glomerulonephritis

(B) Immune complex-
mediated
glomerulonephritis



Goodpasture's

Systemic Lupus Erythematosus (SLE) Abbas 18-3

Some proteins implicated in the etiology of SLE

Candidate activity	Role	Deficiency in SLE
Antigen clearance	Binding and clearance of autoantigens and immune complexes	Complement proteins: C1q, C1r, and C1s, C4>>C2 Serum IgM
	Masking or digestion of DNA and chromatin	Serum amyloid P component DNase 1
Tolerance induction	Threshold for lymphocyte activation	Lyn SHP-1 CD22 FcγRIIB
	Deletion of autoreactive lymphocytes	Fas and Fas ligand Cell-cycle inhibitor p21
Organ-specific manifestations of autoimmunity	Renal disease	FcγRIIB polymorphism FcγRIII polymorphism

Fig 13.7 © 2001 Garland Science

ASSOCIATIONS OF HLA serotype with susceptibility to autoimmune disease

Disease	HLA allele	Relative risk	Sex ratio (♀:♂)
Ankylosing spondylitis	B27	87.4	0.3
Acute anterior uveitis	B27	10	<0.5
Goodpasture's syndrome	DR2	15.9	~1
Multiple sclerosis	DR2	4.8	10
Graves' disease	DR3	3.7	4–5
Myasthenia gravis	DR3	2.5	~1
Systemic lupus erythematosus	DR3	5.8	10–20
Type I insulin-dependent diabetes mellitus	DR3/DR4 heterozygote	~25	~1
Rheumatoid arthritis	DR4	4.2	3
Pemphigus vulgaris	DR4	14.4	~1
Hashimoto's thyroiditis	DR5	3.2	4–5

Associations of infection with immune-mediated tissue damage

Infection	HLA association	Consequence
Group A streptococcus	?	Rheumatic fever (carditis, polyarthritis)
<i>Chlamydia trachomatis</i>	HLA-B27	Reiter's syndrome (arthritis)
<i>Shigella flexneri</i> , <i>Salmonella typhimurium</i> , <i>S. enteritidis</i> , <i>Yersinia enterocolitica</i> , <i>Campylobacter jejuni</i>	HLA-B27	Reactive arthritis
<i>Borrelia burgdorferi</i>	HLA-DR2, DR4	Chronic arthritis in Lyme disease

TABLE 16-3**Molecular mimicry between
proteins of infectious organisms
and human host proteins**

Protein*	Sequence†
Human cytomegalovirus IE2 HLA-DR molecule	79 PDPLGRPDED 60 VTELGRPDAE
Poliovirus VP2 Acetylcholine receptor	70 STTKESRGTT 176 TVIKESRGTK
Papilloma virus E2 Insulin receptor	76 SLHLES LKDS 66 VYGLES LKDL
Rabies virus glycoprotein Insulin receptor	147 TKESLV I I S 764 NKESLV I S E
<i>Klebsiella pneumoniae</i> nitrogenase HLA-B27 molecule	186 SRQTDREDE 70 KAQTDREDL
Adenovirus 12 E1B α-Gliadin	384 LRRGMFRPSQCN 206 LGQGSFRPSQQN
Human immunodeficiency virus p24 Human IgG constant region	160 GVETTTPS 466 GVETTTPS
Measles virus P3 Corticotropin	13 LECIRALK 18 LECIRACK
Measles virus P3 Myelin basic protein	31 EISDNLGQE 61 EISFKLGQE

Cell 50:819 (1987)




Figure 16-13a
Kuby IMMUNOLOGY, Sixth Edition
 © 2007 W. H. Freeman and Company





Figure 16-13b
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W. H. Freeman and Company

Mechanism of Autoimmunity

Failure of Central Tolerance

Thymic Selection is Flawed

Peripheral Tolerance Defective

Failure of activation induced Cell death --AICD

Hyper Immune response

Cytokine Imbalance

Abnormal expression of co-stimulatory molecules

Cross-Reactivity






Figure 16-12
Kuby IMMUNOLOGY, Sixth Edition
 © 2007 W. H. Freeman and Company

TABLE 16-2 **Experimental animal models of autoimmune diseases**


Animal model	Possible human disease counterpart	Inducing antigen	Disease transferred by T cells
SPONTANEOUS AUTOIMMUNE DISEASES			
Nonobese diabetic (NOD) mouse	Insulin-dependent diabetes mellitus (IDDM)	Unknown	Yes
(NZB × NZW) F₁ mouse	Systemic lupus erythematosus (SLE)	Unknown	Yes
Obese-strain chicken	Hashimoto's thyroiditis	Thyroglobulin	Yes
EXPERIMENTALLY INDUCED AUTOIMMUNE DISEASES*			
Experimental autoimmune myasthenia gravis (EAMG)	Myasthenia gravis	Acetylcholine receptor	Yes
Experimental autoimmune encephalomyelitis (EAE)	Multiple sclerosis (MS)	Myelin basic protein (MBP); proteolipid protein (PLP)	Yes
Autoimmune arthritis (AA)	Rheumatoid arthritis	<i>M. tuberculosis</i> (proteoglycans)	Yes
Experimental autoimmune thyroiditis (EAT)	Hashimoto's thyroiditis	Thyroglobulin	Yes
*These diseases can be induced by injecting appropriate animals with the indicated antigen in complete Freund's adjuvant. Except for autoimmune arthritis, the antigens used correspond to the self antigens associated with the human disease counterpart. Rheumatoid arthritis involves reaction to proteoglycans, which are self antigens associated with connective tissue.			

Mice injected with myelin basic protein and complete Freund's adjuvant develop demyelinating disease (EAE)





(b) paralysis

The disease is mediated by myelin basic protein-specific inflammatory T cells (T_H1)




Disease can be transmitted by transfer of T cells from affected animal



paralysis

New Therapies

- **Induce Tolerance--oral feeding of self-proteins**
- **Remove T cells--inject TCR peptides use anti-CD4**
- **Decoys (altered peptide) -make analogs of self peptide that bind to MHC Class II with high affinity but do not stimulate T cells**
- **Anti-inflammatory cytokines (anti-TNF)= Engineered EMBREL TNFR/IgG FC - binds TNF and removes it**






Figure 16-14
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W. H. Freeman and Company






Figure 16-15
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W. H. Freeman and Company

(a) Activation of MBP-specific T_H1 cells activates macrophages. Activated macrophages damage oligodendrocytes, causing demyelination of neurons




(b)

**Antibodies to MHC class II molecules
block T-cell activation and
inhibit demyelination**




(b) Immunosuppressive drugs kill dividing cells or inhibit inflammation

Cyclophosphamide



(c) Immunosuppressive drugs kill
dividing cells or inhibit inflammation

Prednisone



(c) Current Biology Ltd/Garland Publishing